{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "37904402", "DateCompleted": {"Year": "2023", "Month": "11", "Day": "02"}, "DateRevised": {"Year": "2024", "Month": "02", "Day": "08"}, "Article": {"Language": ["eng"], "ArticleDate": [], "ELocationID": ["e34276", "10.1097/MD.0000000000034276"], "Journal": {"ISSN": "1536-5964", "JournalIssue": {"Volume": "102", "Issue": "43", "PubDate": {"Year": "2023", "Month": "Oct", "Day": "27"}}, "Title": "Medicine", "ISOAbbreviation": "Medicine (Baltimore)"}, "ArticleTitle": "Air pollution impede ALT normalization in chronic hepatitis B patients treated with nucleotide/nucleoside analogues.", "Pagination": {"StartPage": "e34276", "MedlinePgn": "e34276"}, "Abstract": {"AbstractText": ["Biochemical response is an important prognostic indicator in chronic hepatitis B (CHB) patients receiving nucleotide/nucleoside analogues (NAs). However, the effects of air pollution in alanine aminotransferase (ALT) normalization remain elusive. This longitudinal study recruited 80 hepatitis B e antigen-negative CHB patients who received NAs. ALT levels were measured during the first year of anti-hepatitis B virus therapy. Normal ALT levels were defined as\u2005<19 U/L for females and\u2005<30 U/L for males, and the risk factors associated with ALT abnormalities were analyzed. The daily estimations of air pollutants (particulate matter\u2005\u22642.5 \u00b5m in diameter (PM2.5), nitrogen dioxide, ozone (O3), and benzene) were aggregated into the mean estimation for the previous month based on the date of recruitment (baseline) and 1 year later. Sixteen patients (20.0%) had a baseline ALT\u2005>\u200540 U/L; overall, 41 (51.6%) had an abnormal ALT (\u226519 U/L for females and\u2005\u2265\u200530 U/L for males). After 1 year of NA therapy, 75 patients (93.8%) had undetectable hepatitis B virus DNA levels. Mean post-treatment ALT levels were significantly lower than mean pretreatment levels (21.3 vs 30.0 U/L, respectively; P\u2005<\u2005.001). The proportion of patients with a normal ALT was also significantly higher after versus before treatment (71.2% vs 51.2%, respectively; P\u2005=\u2005.001). The strongest factors associated with ALT abnormality after 1 year of NA treatment were body mass index (odds ratio [OR], 1.28; 95% confidence interval [CI], 1.05-1.54; P\u2005=\u2005.01) and ozone level (OR, 1.11; 95% CI, 1.02-1.22; P\u2005=\u2005.02). Among hepatitis B e antigen-negative CHB patients with relatively low viral loads, 1 year of NA treatment improved ALT levels after the adjustment for confounding factors and increased the proportion of patients with normal ALT levels. Air pollution affects the efficacy of ALT normalization."], "CopyrightInformation": "Copyright \u00a9 2023 the Author(s). Published by Wolters Kluwer Health, Inc."}, "AuthorList": [{"Identifier": ["0000-0003-2961-130"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Ph.D. Program in Environmental and Occupational Medicine, College of Medicine, Kaohsiung Medical University and National Health Research Institutes, Kaohsiung, Taiwan."}, {"Identifier": [], "Affiliation": "Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan."}, {"Identifier": [], "Affiliation": "Department of Internal Medicine, Pingtung Hospital, Ministry of Health and Welfare, Ping-Tung, Taiwan."}], "LastName": "Jang", "ForeName": "Tyng-Yuan", "Initials": "TY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Environmental and Occupational Health Sciences, National Taiwan University, Taipei, Taiwan."}], "LastName": "Ho", "ForeName": "Chi-Chang", "Initials": "CC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Geomatics, National Cheng Kung University, Tainan, Taiwan."}, {"Identifier": [], "Affiliation": "Innovation and Development Center of Sustainable Agriculture, National Chung Hsing University, Tainan, Taiwan."}], "LastName": "Wu", "ForeName": "Chih-Da", "Initials": "CD"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan."}], "LastName": "Dai", "ForeName": "Chia-Yen", "Initials": "CY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Environmental and Occupational Health Sciences, National Taiwan University, Taipei, Taiwan."}, {"Identifier": [], "Affiliation": "Department of Public Health, National Taiwan University, Taipei, Taiwan."}, {"Identifier": [], "Affiliation": "Department of Environmental and Occupational Medicine, National Taiwan University Hospital, Taipei, Taiwan."}, {"Identifier": [], "Affiliation": "National Institute of Environmental Health Sciences, National Health Research Institutes, Miaoli, Taiwan."}], "LastName": "Chen", "ForeName": "Pau-Chung", "Initials": "PC"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Medicine (Baltimore)", "NlmUniqueID": "2985248R", "ISSNLinking": "0025-7974"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antiviral Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Nucleosides"}, {"RegistryNumber": "0", "NameOfSubstance": "Nucleotides"}, {"RegistryNumber": "0", "NameOfSubstance": "Hepatitis B e Antigens"}, {"RegistryNumber": "EC 2.6.1.2", "NameOfSubstance": "Alanine Transaminase"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}, {"RegistryNumber": "0", "NameOfSubstance": "DNA, Viral"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Hepatitis B, Chronic"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Antiviral Agents"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Nucleosides"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Nucleotides"}, {"QualifierName": [], "DescriptorName": "Hepatitis B e Antigens"}, {"QualifierName": [], "DescriptorName": "Longitudinal Studies"}, {"QualifierName": ["genetics"], "DescriptorName": "Hepatitis B virus"}, {"QualifierName": [], "DescriptorName": "Alanine Transaminase"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Air Pollution"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Ozone"}, {"QualifierName": [], "DescriptorName": "DNA, Viral"}], "CoiStatement": "The authors have no funding and conflicts of interest to disclose."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Hu YC, Yeh CC, Chen RY, et al. . Seroprevalence of hepatitis B virus in Taiwan 30 years after the commencement of the national vaccination program. PeerJ. 2018;6:e4297.", "ArticleIdList": ["PMC5817935", "29472994"]}, {"Citation": "Yang JF, Lin CI, Huang JF, et al. . Viral hepatitis infections in southern Taiwan: a multicenter community-based study. Kaohsiung J Med Sci. 2010;26:461\u20139.", "ArticleIdList": ["20837342"]}, {"Citation": "Grossi G, Vigano M, Loglio A, et al. . Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs). Liver Int. 2017;37(Suppl 1):45\u201351.", "ArticleIdList": ["28052621"]}, {"Citation": "Huang DQ, Yeo YH, Tan E, et al. . ALT levels for Asians with metabolic diseases: a meta-analysis of 86 studies with individual patient data validation. Hepatol Commun. 2020;4:1624\u201336.", "ArticleIdList": ["PMC7603525", "33163833"]}, {"Citation": "Terrault NA, Bzowej NH, Chang KM, et al. . AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261\u201383.", "ArticleIdList": ["PMC5987259", "26566064"]}, {"Citation": "Chien RN, Kao JH, Peng CY, et al. . Taiwan consensus statement on the management of chronic hepatitis B. J Formosan Med Assoc. 2019;118:7\u201338.", "ArticleIdList": ["30527436"]}, {"Citation": "Sarin SK, Kumar M, Lau GK, et al. . Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1\u201398.", "ArticleIdList": ["PMC4722087", "26563120"]}, {"Citation": "European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370\u201398.", "ArticleIdList": ["28427875"]}, {"Citation": "Buti M, Gane E, Seto WK, et al. . Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196\u2013206.", "ArticleIdList": ["28404092"]}, {"Citation": "Wong GL, Chan HL, Tse YK, et al. . Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. J Hepatol. 2018;69:793\u2013802.", "ArticleIdList": ["29758335"]}, {"Citation": "Li FR, Liao J, Zhu B, et al. . Long-term exposure to air pollution and incident non-alcoholic fatty liver disease and cirrhosis: a cohort study. Liver Int. 2023;43:299\u2013307.", "ArticleIdList": ["36069651"]}, {"Citation": "VoPham T, Bertrand KA, Tamimi RM, et al. . Ambient PM(2.5) air pollution exposure and hepatocellular carcinoma incidence in the United States. Cancer Causes Control. 2018;29:563\u201372.", "ArticleIdList": ["PMC5940508", "29696510"]}, {"Citation": "Guo B, Guo Y, Nima Q, et al. . Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease. J Hepatol. 2022;76:518\u201325.", "ArticleIdList": ["34883157"]}, {"Citation": "Zheng Z, Zhang X, Wang J, et al. . Exposure to fine airborne particulate matters induces hepatic fibrosis in murine models. J Hepatol. 2015;63:1397\u2013404.", "ArticleIdList": ["PMC5003300", "26220751"]}, {"Citation": "Lin YY, Huang JF, Liu SF, et al. . Performance characteristics of two real-time PCR assays for quantification of hepatitis B virus DNA. Scand J Infect Dis. 2009;41:614\u20138.", "ArticleIdList": ["19360504"]}, {"Citation": "Saadeh S, Younossi ZM, Remer EM, et al. . The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745\u201350.", "ArticleIdList": ["12198701"]}, {"Citation": "Huber A, Ebner L, Heverhagen JT, et al. . State-of-the-art imaging of liver fibrosis and cirrhosis: A comprehensive review of current applications and future perspectives. Eur J Radiol Open. 2015;2:90\u2013100.", "ArticleIdList": ["PMC4750581", "26937441"]}, {"Citation": "Wu CD, Zeng YT, Lung SC. A hybrid kriging/land-use regression model to assess PM(2.5) spatial-temporal variability. Sci Total Environ. 2018;645:1456\u201364.", "ArticleIdList": ["30248867"]}, {"Citation": "Hsu CY, Wu JY, Chen YC, et al. . Asian culturally specific predictors in a large-scale land use regression model to predict spatial-temporal variability of ozone concentration. Int J Environ Res Public Health. 2019;16:1300.", "ArticleIdList": ["PMC6480950", "30978985"]}, {"Citation": "Hsu CY, Xie HX, Wong PY, et al. . A mixed spatial prediction model in estimating spatiotemporal variations in benzene concentrations in Taiwan. Chemosphere. 2022;301:134758.", "ArticleIdList": ["35490755"]}, {"Citation": "Jang TY, Wei YJ, Yeh ML, et al. . Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. J Formosan Med Assoc. 2021;120:303\u201310.", "ArticleIdList": ["33109431"]}, {"Citation": "Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 2022;28:276\u2013331.", "ArticleIdList": ["PMC9013624", "35430783"]}, {"Citation": "Chen CJ, Yang HI, Su J, et al. . Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65\u201373.", "ArticleIdList": ["16391218"]}, {"Citation": "Hsu YS, Chien RN, Yeh CT, et al. . Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522\u20137.", "ArticleIdList": ["12029639"]}, {"Citation": "Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology. 2007;45:1187\u201392.", "ArticleIdList": ["17465003"]}, {"Citation": "Cao Z, Liu Y, Ma L, et al. . A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha. Hepatology. 2017;66:1058\u201366.", "ArticleIdList": ["28407271"]}, {"Citation": "de Niet A, Jansen L, Stelma F, et al. . Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial. Lancet Gastroenterol Hepatol. 2017;2:576\u201384.", "ArticleIdList": ["28522204"]}, {"Citation": "Ferreira SC, Chacha SG, Souza FF, et al. . Factors associated with spontaneous HBsAg clearance in chronic hepatitis B patients followed at a university hospital. Ann Hepatol. 2014;13:762\u201370.", "ArticleIdList": ["25332262"]}, {"Citation": "Poh Z, Goh BB, Chang PE, et al. . Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance: a 10-year follow-up of 673 patients. Eur J Gastroenterol Hepatol. 2015;27:638\u201343.", "ArticleIdList": ["PMC4415961", "25831135"]}, {"Citation": "Barcena Marugan R, Garcia Garzon S. DNA-guided hepatitis B treatment, viral load is essential, but not sufficient. World J Gastroenterol. 2009;15:423\u201330.", "ArticleIdList": ["PMC2653363", "19152446"]}, {"Citation": "Choi J, Kim HJ, Lee J, et al. . Risk of hepatocellular carcinoma in patients treated with Entecavir vs Tenofovir for chronic hepatitis B: A Korean Nationwide Cohort Study. JAMA Oncol. 2019;5:30\u20136.", "ArticleIdList": ["PMC6439769", "30267080"]}, {"Citation": "Yim HJ, Kim JH, Park JY, et al. . Comparison of clinical practice guidelines for the management of chronic hepatitis B: when to start, when to change, and when to stop. Clin Mol Hepatol. 2020;26:411\u201329.", "ArticleIdList": ["PMC7641563", "32854458"]}, {"Citation": "Liang LY, Wong GL. Unmet need in chronic hepatitis B management. Clin Mol Hepatol. 2019;25:172\u201380.", "ArticleIdList": ["PMC6589853", "30754963"]}, {"Citation": "Jang TY. Letter: improved alanine aminotransferase level in patients with chronic hepatitis B without cirrhosis and low viral load treated with nucleotide/nucleoside analogues. Aliment Pharmacol Ther. 2023;57:587\u20138.", "ArticleIdList": ["36786461"]}, {"Citation": "Kim J, Jo I. Relationship between body mass index and alanine aminotransferase concentration in non-diabetic Korean adults. Eur J Clin Nutr. 2010;64:169\u201375.", "ArticleIdList": ["19904291"]}, {"Citation": "Newsome PN, Cramb R, Davison SM, et al. . Guidelines on the management of abnormal liver blood tests. Gut. 2018;67:6\u201319.", "ArticleIdList": ["PMC5754852", "29122851"]}, {"Citation": "Yeh ML, Liang PC, Trinh S, et al. . Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide. J Formos Med Assoc. 2022;121:1273\u201382.", "ArticleIdList": ["34625346"]}, {"Citation": "Li Y, Yuan X, Wei J, et al. . Long-term exposure to ambient air pollution and serum liver enzymes in older adults: a population-based longitudinal study. Ann Epidemiol. 2022;74:1\u20137.", "ArticleIdList": ["35680103"]}, {"Citation": "Zhang Y, Li Z, Luo Q, et al. . Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: a prospective real-world clinical study. Antivir Ther. 2022;27:135965352210823."}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "11", "Day": "2", "Hour": "12", "Minute": "42"}, {"Year": "2023", "Month": "10", "Day": "31", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "10", "Day": "31", "Hour": "1", "Minute": "40"}, {"Year": "2023", "Month": "10", "Day": "27"}], "PublicationStatus": "ppublish", "ArticleIdList": ["37904402", "PMC10615411", "10.1097/MD.0000000000034276", "00005792-202310270-00058"]}}], "PubmedBookArticle": []}